NCT04679493 - Study to Assess Safety, Tolerability and Pharmacokinetics of XC7 (Which is Planned Use in the Treatment of COVID-19) in Healthy Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 17, 2020

Primary Completion Date

April 9, 2021

Study Completion Date

April 9, 2021

Conditions

Covid19Healthy Volunteers

Interventions

DRUG

XC7 100 mg single

The volunteers will receive a single dose of the ID (1 capsule once, 100 mg)

DRUG

XC7 200 mg single

The volunteers will receive a single dose of the ID (2 capsules once, 100 mg each)

DRUG

Placebo single

The volunteers will receive a single dose of the ID (1 or 2 capsules once)

DRUG

XC7 200 mg multiple

The volunteers will receive multiple doses of the ID during 14 days (2 capsules daily, 100 mg each)

DRUG

Placebo multiple

The volunteers will receive multiple doses of the ID during 14 days (2 capsules daily)

Trial Locations (1)

119991

"Federal State Autonomous Educational Institution of Higher Education The First Moscow State Medical University named after I.M. Sechenov of the Ministry of Health of the Russian Federation", Moscow